Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?
作者信息
Gainford M C, Dranitsaris G, Ooi W, Vanhuyse M, Clemons M
出版信息
Curr Oncol. 2006 Oct;13(5):187-90. doi: 10.3390/curroncol13050018.
Abstract
摘要
相似文献
1
Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?比较双膦酸盐在临床试验中的使用结果与实际应用情况：这是苹果与橙子的比较吗？
Curr Oncol. 2006 Oct;13(5):187-90. doi: 10.3390/curroncol13050018.
2
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨治疗药物。
Cochrane Database Syst Rev. 2017 Oct 30;10(10):CD003474. doi: 10.1002/14651858.CD003474.pub4.
3
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2005 Jul 20(3):CD003474. doi: 10.1002/14651858.CD003474.pub2.
4
Bisphosphonates for breast cancer.用于乳腺癌的双膦酸盐类药物。
Cochrane Database Syst Rev. 2002(1):CD003474. doi: 10.1002/14651858.CD003474.
5
Bisphosphonates and other bone agents for breast cancer.用于乳腺癌的双膦酸盐及其他骨药物。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD003474. doi: 10.1002/14651858.CD003474.pub3.
6
Prevention of bone metastases from breast cancer by adjuvant bisphosphonate therapy.辅助性双膦酸盐治疗预防乳腺癌骨转移
Breast Cancer. 2003;10(1):33-7. doi: 10.1007/BF02967623.
7
Bisphosphonates and their Role in Therapy for Breast Cancer - Results from the PATH Biobank.双膦酸盐及其在乳腺癌治疗中的作用——PATH生物样本库的研究结果
Geburtshilfe Frauenheilkd. 2013 May;73(5):412-421. doi: 10.1055/s-0032-1328502.
8
Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer.双膦酸盐疗法治疗乳腺癌骨转移的临床疗效
Breast Cancer. 2003;10(1):28-32. doi: 10.1007/BF02967622.
9
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.美国临床肿瘤学会关于双膦酸盐在乳腺癌中作用的指南。美国临床肿瘤学会双膦酸盐专家小组。
J Clin Oncol. 2000 Mar;18(6):1378-91. doi: 10.1200/JCO.2000.18.6.1378.
10
Treatment of breast cancer with bone metastasis: bisphosphonate treatment - current and future.乳腺癌骨转移的治疗：双膦酸盐治疗——现状与未来。
Int J Clin Oncol. 2008 Feb;13(1):18-23. doi: 10.1007/s10147-007-0726-2. Epub 2008 Feb 29.
引用本文的文献
1
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers.肿瘤相关巨噬细胞作为甲状腺癌潜在的治疗靶点。
Cancer Immunol Immunother. 2023 Dec;72(12):3895-3917. doi: 10.1007/s00262-023-03549-6. Epub 2023 Oct 5.
2
Review of Bone Modifying Agents in Metastatic Breast Cancer.转移性乳腺癌中骨修饰剂的综述
Cureus. 2021 Feb 13;13(2):e13332. doi: 10.7759/cureus.13332.
本文引用的文献
1
Can bone markers guide more effective treatment of bone metastases from breast cancer?骨标志物能否指导更有效地治疗乳腺癌骨转移？
Breast Cancer Res Treat. 2006 May;97(1):81-90. doi: 10.1007/s10549-005-9094-7. Epub 2005 Dec 1.
2
Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer.双膦酸盐在转移性乳腺癌患者中的试验外评估。
BMC Cancer. 2005 Jul 28;5:89. doi: 10.1186/1471-2407-5-89.
3
Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?乳腺癌骨转移的全身治疗：它真有人们所说的那么好吗？
J Clin Oncol. 2005 Jul 20;23(21):4802-3; author reply 4803. doi: 10.1200/JCO.2005.01.3490.
4
Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid.骨吸收和形成标志物在接受双膦酸盐唑来膦酸治疗的骨转移癌患者中的预测价值。
J Clin Oncol. 2005 Aug 1;23(22):4925-35. doi: 10.1200/JCO.2005.06.091. Epub 2005 Jun 27.
5
Recent developments in bisphosphonates for patients with metastatic breast cancer.用于转移性乳腺癌患者的双膦酸盐类药物的最新进展。
BMJ. 2005 Apr 2;330(7494):769-73. doi: 10.1136/bmj.330.7494.769.
6
Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.在患有乳腺癌骨转移的日本女性中，与安慰剂相比，唑来膦酸显著降低骨骼并发症：一项随机、安慰剂对照试验。
J Clin Oncol. 2005 May 20;23(15):3314-21. doi: 10.1200/JCO.2005.05.116. Epub 2005 Feb 28.
7
Bisphosphonate use for the management of breast cancer patients with bone metastases: a survey of Canadian Medical Oncologists.双膦酸盐用于治疗有骨转移的乳腺癌患者：加拿大肿瘤内科医生的一项调查
Support Care Cancer. 2004 Dec;12(12):852-8. doi: 10.1007/s00520-004-0671-9. Epub 2004 Aug 21.
8
Do physicians follow systemic treatment and funding policy guidelines?医生是否遵循系统治疗和资金政策指南？
Can J Clin Pharmacol. 2004 Spring;11(1):e168-78.
9
Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.口服伊班膦酸钠治疗乳腺癌转移性骨病：一项随机、双盲、安慰剂对照试验的疗效和安全性结果
Ann Oncol. 2004 May;15(5):743-50. doi: 10.1093/annonc/mdh173.
10
Should all breast cancer patients with symptomatic bone metastases be treated with bisphosphonates? The case in support.
Clin Oncol (R Coll Radiol). 2004 Apr;16(2):108-11. doi: 10.1016/j.clon.2004.01.004.
Zotero 插件